-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai Mengke Pharmaceutical Co.
, Ltd.
(referred to as "Mengke Pharmaceutical") has been accepted for its application for listing on the Science and Technology Innovation Board.
141 million yuan will be used for marketing channel upgrades and academic promotion projects; 200 million yuan will be used to supplement working capital projects
.
The prospectus shows that the company is an innovative biomedical company with global independent intellectual property rights and international competitiveness, focusing on the treatment of infectious diseases.
It is committed to discovering, developing and commercializing innovative drugs for unmet clinical needs
.
Financial data shows that the company has not yet achieved profitability
.
In 2018, 2019, 2020, and the first half of 2021, losses were 150 million yuan, 115 million yuan, 86,327,200 yuan, and 86,805,800 yuan respectively
.
In this regard, the company chose the fifth set of listing criteria on the Science and Technology Innovation Board this time, that is: the estimated market value is not less than RMB 4 billion, and the main business or product needs to be approved by the relevant state departments.
The market space is large.
Results
.
Companies in the pharmaceutical industry need to have at least one core product approved to carry out Phase II clinical trials, and other companies that meet the positioning of the science and technology innovation board need to have obvious technical advantages and meet corresponding conditions
.
As of the signing date of this prospectus, the company has successfully completed 10 phase I clinical trials, 3 phase II clinical trials and 1 phase III clinical trial worldwide, and 1 phase I clinical trial is underway
.
Among them, the company's first self-designed and developed new-generation oxazolidinone antibacterial drug product-Contizolamide, can be used to treat infections caused by multi-drug-resistant gram-positive bacteria
.
The product Kang has completed Phase I, Phase II and Phase III clinical trials in China, Phase I clinical trials in Australia and Phase II in the United States
.
At the same time, the water-soluble prodrug MRX-4 of contizolamide can be converted into contizolamide to exert its efficacy.
It has completed the Phase II clinical trial in the United States in 2019 and completed the Phase I clinical trial in China in 2021.
test
.
MRX-8 is used to treat multi-drug-resistant Gram-negative bacteria infections.
It is currently in the phase I clinical trial phase in the United States and has applied for China's IND application
.
In addition to the three core products of Contizolamide, MRX-4, and MRX-8 that have entered the clinical and/or commercialization stage, the company also has a number of new anti-drug-resistant bacteria drugs in the preclinical stage, such as kidney cancer, Nephritis drugs and anti-coronavirus drug pipeline
.
Since 2020, Mengke Pharmaceutical has completed two rounds of financing in succession.
They are the nearly 300 million yuan round D financing completed on August 5, 2020.
This round of financing was led by Huagai Capital, Sinopharm Zhongjin Medical Industry Fund and Qing Science and Technology Asset Management jointly participate in the investment
.
The funds raised will be mainly used to promote and expand clinical pipeline research and development, as well as the full independent commercialization of the Chinese market, and the E round of financing (including new and existing shares) of more than 700 million yuan at the end of 2020.
This round of financing will be funded by Legend Capital Leading the investment, Yingke Capital, Founder Hesheng, China Merchants Securities, Detong Capital, KIP, Zhongtai Venture Capital and other institutions jointly participated.
The funds raised will be mainly used for research on new drugs to expand indications and promote subsequent international multi-center clinical trials , Expansion of the pipeline of R&D products, and independent commercialization of the Chinese market
.
Prior to this, Mengke Pharmaceutical had also received investment from institutions such as Delian Capital
.
, Ltd.
(referred to as "Mengke Pharmaceutical") has been accepted for its application for listing on the Science and Technology Innovation Board.
141 million yuan will be used for marketing channel upgrades and academic promotion projects; 200 million yuan will be used to supplement working capital projects
.
The prospectus shows that the company is an innovative biomedical company with global independent intellectual property rights and international competitiveness, focusing on the treatment of infectious diseases.
It is committed to discovering, developing and commercializing innovative drugs for unmet clinical needs
.
Financial data shows that the company has not yet achieved profitability
.
In 2018, 2019, 2020, and the first half of 2021, losses were 150 million yuan, 115 million yuan, 86,327,200 yuan, and 86,805,800 yuan respectively
.
In this regard, the company chose the fifth set of listing criteria on the Science and Technology Innovation Board this time, that is: the estimated market value is not less than RMB 4 billion, and the main business or product needs to be approved by the relevant state departments.
The market space is large.
Results
.
Companies in the pharmaceutical industry need to have at least one core product approved to carry out Phase II clinical trials, and other companies that meet the positioning of the science and technology innovation board need to have obvious technical advantages and meet corresponding conditions
.
As of the signing date of this prospectus, the company has successfully completed 10 phase I clinical trials, 3 phase II clinical trials and 1 phase III clinical trial worldwide, and 1 phase I clinical trial is underway
.
Among them, the company's first self-designed and developed new-generation oxazolidinone antibacterial drug product-Contizolamide, can be used to treat infections caused by multi-drug-resistant gram-positive bacteria
.
The product Kang has completed Phase I, Phase II and Phase III clinical trials in China, Phase I clinical trials in Australia and Phase II in the United States
.
At the same time, the water-soluble prodrug MRX-4 of contizolamide can be converted into contizolamide to exert its efficacy.
It has completed the Phase II clinical trial in the United States in 2019 and completed the Phase I clinical trial in China in 2021.
test
.
MRX-8 is used to treat multi-drug-resistant Gram-negative bacteria infections.
It is currently in the phase I clinical trial phase in the United States and has applied for China's IND application
.
In addition to the three core products of Contizolamide, MRX-4, and MRX-8 that have entered the clinical and/or commercialization stage, the company also has a number of new anti-drug-resistant bacteria drugs in the preclinical stage, such as kidney cancer, Nephritis drugs and anti-coronavirus drug pipeline
.
Since 2020, Mengke Pharmaceutical has completed two rounds of financing in succession.
They are the nearly 300 million yuan round D financing completed on August 5, 2020.
This round of financing was led by Huagai Capital, Sinopharm Zhongjin Medical Industry Fund and Qing Science and Technology Asset Management jointly participate in the investment
.
The funds raised will be mainly used to promote and expand clinical pipeline research and development, as well as the full independent commercialization of the Chinese market, and the E round of financing (including new and existing shares) of more than 700 million yuan at the end of 2020.
This round of financing will be funded by Legend Capital Leading the investment, Yingke Capital, Founder Hesheng, China Merchants Securities, Detong Capital, KIP, Zhongtai Venture Capital and other institutions jointly participated.
The funds raised will be mainly used for research on new drugs to expand indications and promote subsequent international multi-center clinical trials , Expansion of the pipeline of R&D products, and independent commercialization of the Chinese market
.
Prior to this, Mengke Pharmaceutical had also received investment from institutions such as Delian Capital
.
